Literature DB >> 2074253

Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers.

A Bryskier1, T Procyk, D Tremblay, B Lenfant, J B Fourtillan.   

Abstract

Cefodizime is a new third generation cephalosporin for parenteral use. The purpose of this study was to define the pharmacokinetic profile of cefodizime after intravenous dosing with 1.0 and 2.0 g in healthy adult volunteers. Concentrations in plasma were determined over a period of 34 h and in urine over 48 h, using high-pressure liquid chromatographic procedures. Cefodizime displays a long elimination half-life (3.5-3.7 h). Mean total clearance was 2.63 +/- 0.19 l/h and mean renal clearance was 1.37 +/- 0.15 l/h. Areas under the curve were 422 +/- 43 mg.h/l and 757 +/- 39 mg.h/l for 1.0 and 2.0 g respectively. The apparent volumes of distribution were 12.8 +/- 1.81 and 14.3 +/- 1.11. After 1.0 g administration the residual concentrations were 3.94 +/- 0.79 mg/l and 0.38 +/- 0.10 mg/l at 12 and 24 h, respectively; after 2.0 g administration the residual concentrations were 6.80 +/- 1.40 mg/l and 0.65 +/- 0.18 mg/l, at 12 h and 24 h. Cefodizime is mainly eliminated via the kidneys. This profile supports once-daily administration of cefodizime, when indicated in non-life-threatening infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2074253     DOI: 10.1093/jac/26.suppl_c.65

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 2.  Pharmacokinetic profile of cefodizime.

Authors:  D Brockmeier; E E Dagrosa
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 3.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

4.  Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.

Authors:  B Lenfant; F Namour; C Logeais; D Coussediere; O Rivault; A Bryskier; A Surjus
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 5.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.